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Patients and methods: 70 patients with a recent occurrence of DCM with left ventricle
ejection fraction (LVEF) o40% and with the history of symptoms less than 12 months were
enrolled to observation. In EMB samples the average number of T-lymphocytes (CD3þ cells)
and mononuclear leucocytes (LCAþ cells) in mm was determined. The presence of2
inflammation was evaluated as positive in case of the findings of 47 CD3þ cells and/or
414 LCAþ cells in mm . The detection of pathological agents in myocardium was2
performed by quantitative polymerase chain reaction (PCR).
Results: According to immunohistological (IH) assessment findings were positive (IHþ) in
35 patients (i.e. 50%); thus the inflammatory infiltration was present in myocardium. In
remaining patients the findings were negative (IH). At 6 months follow-up, in the group of
IHþ patients the LVEF improved from 2579% to 39711% and NYHA class declined from
2.870.5 to 1.770.6 (both po0.001). In IH group change in LVEF (from 2378% to 27710%)
in contrast to the change of NYHA class (from 2.570.5 to 2.170.7; po0.05) was not found
statistically significant. Comparing changes in the parameters between both groups, the
IHþ group has significantly more improved in LVEF (po0.01) as well as in the NYHA class
(po0.001). Viral genome was detected (PCR was positive, PCRþ) in 43 patients (i.e. 61%). At 6
months follow-up, there were statistically significant changes of LVEF in PCRþ group (from
2578% to 34712%; po0.01) and also in PCR group (from 2278% to 32712%; po0.001).
The difference in changes of LVEF between these two groups was not statistically significant.
Change in NYHA class was statistically significant and comparably reduced in both groups
(from 2.670.5 to 1.970.6; po0.001; and from 2.770.6 to 2.070.7; po0.001, respectively).
Conclusion: Patientswith a recent occurrence of non-ischemic LV dysfunction and biopsy proven
myocarditis have been found to show statistically significant improvement in the LV systolicch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
ovascular Diseases, St. Anne’s University Hospital, International Clinical Research Center,
el.: þ420 734 161 396; fax: þ420 543 182 205.
ejci@fnusa.cz (J. Krejcˇı´).
.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 3 3 – e 3 4 0e334function and functional status in comparison to the group of patients with no evidence of
inflammatory infiltration in 6-month follow-up. On the contrary, the presence or absence of
viruses in the myocardium has no impact on the changes in these parameters.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Heart failure is one of the most medically and economically
important problems in present cardiology. Currently, the most
common cause of terminal heart failure leading to heart trans-
plantation is dilated cardiomyopathy (DCM) [1]. Much effort in
searching for genetic causes of this disease has beenmade in the
last decades, but these were only identified in 20–50% of cases.
Most cases were regarded as idiopathic DCM [2].
Results of trials focused on bioptic diagnostics of DCM
showed that approximately 50% of cases initially regarded as
‘‘idiopathic’’ DCM had an important inflammatory infiltration in
myocardium [3,4]. In these cases, therefore, DCM is caused by
myocarditis; this is referred to as inflammatory cardiomyopathy
(ICM). Myocarditis may often resolve spontaneously, which may
be associated in 50–70% cases with the significant improvement
in left ventricle (LV) systolic function or even its complete
normalization [5,6]. In the rest of the cases originally classified
as ICM can despite resolved inflammation persist LV systolic
dysfunction, which may even progress [7]. Today, it is assumed
that most cases of DCM (at the moment with no inflammatory
infiltration detected) occur as a result of previous history of
myocarditis [8]. In some patients maybe LV systolic dysfunction
is associated with continuing or recurrent myocardial
inflammation—such cases would be classified as ICM.
Previously it has been published that in the myocardium
of the patients with DCM viruses, or viral nucleic acid, have
been often (in 44–67% of cases) found [3,9]. The polymerase
chain reaction (PCR) is the most often used method for the
detection of viruses or other pathogenic agents. The impor-
tance of the viral presence in the myocardium is even less
documented than the importance of inflammatory infiltra-
tion. According to some works [3,10,11] the detection of
viruses in the myocardium is an unfavorable prognostic
marker; on the contrary other authors have not shown any
effect of viral presence on LV function [9].
With these new, often surprising, and sometimes contro-
versial findings a revival of interest for bioptic diagnostics of
DCM is related. Apart from the proof of inflammation or viral
presence and their key importance for a correct diagnosis,
the result of endomyocardial biopsy (EMB) is also important
for estimating prognosis and also for taking other therapeutic
decisions [12,13].2. Aim
In this study, we focused on the detection of inflammatory
infiltration and the presence of nucleic acid of a range of
potential pathogens in EMB samples from patients with DCM.
At 6-month follow-up we compared the development inechocardiographic parameters and functional status in the
groups divided according to the presence or absence of
inflammatory infiltration in the myocardium, and also
according to the presence or absence of viruses (or other
pathogens) in the myocardium.3. Patients
There were 70 patients enrolled who had recently developed
DCM with the left ventricle ejection fraction (LVEF)o40% and
with the duration of symptoms up to 12 months who were
receiving standard treatment of heart failure for at least 14
days (especially angiotensin-converting enzyme inhibitors,
angiotensin-II receptor blockers, and beta-blockers, or aldos-
terone antagonists, diuretics and digoxin). In all these
patients coronary angiography was performed to exclude
coronary artery disease as the cause of LV dysfunction, and
the presence of primary valvular heart disease was excluded
by echocardiography. Possible toxonutritive myocardial
damage or endocrine disorders leading to LV dysfunction
were searched for in medical history and laboratory results
which were considered as exclusion criteria. Patients with
impairment of LV systolic function due to tachycardia and
patients who have received chemotherapy in the past were
not included. All patients included in this analysis were
treated only with standard heart failure therapy; no specific
treatment based on the result of EMB was administered.4. Methods
In patients who met inclusion criteria mentioned above and
did not have any of exclusion criteria and who signed an
informed consent, EMB from right ventricle (RV) was per-
formed (preferably from interventricular septum or RV apex).
Four samples for histological and imunohistological analysis
and six samples for PCR analysis were taken. The average
number of T-lymphocytes (CD3þ cells) and mononuclear
leukocytes (LCAþ cells) was determined in mm . The pre-2
sence of inflammation was evaluated as positive in the case
of finding of 47 CD3þ cells and/or 414 LCAþ cells in mm2
[14–17]. The presence of pathological agents in myocardium
was detected with quantitative polymerase chain reaction
(PCR) in real time for parvovirus B19 (PVB19), cytomegalovirus
(CMV), Epstein–Barr virus (EBV), herpes simplex virus 1 and 2
(HSV 1 and 2), human herpes virus 6 (HHV 6), adenovirus
(AV) and Borellia burgdorferi, and with reverse transcription
followed by quantitative PCR in real time for enterovirus (EV).
Echocardiographic examinations were performed using
Vivid E9 (GE, Milwaukee, WI, USA) with M5S probe according
to Guidelines of American Society of Echocardiography and
Table 1 – Comparison of groups of patients according to inflammatory infiltration presence or absence in myocardium.
Parameter IH positive (N¼35) IH negative (N¼35)
Mean (SD) Median (95% CI) p-Value Mean (SD) Median (95% CI) p-Value p-Value
Age (years) Initial value 43.3 (13.44) 43.0 (36.00–49.00) 48.1 (10.37) 50.0 (46.00–52.00) 0.0779
Duration of symptoms (months) Initial value 2.6 (2.94) 1.5 (1.00–2.00) 3.8 (2.63) 3.0 (2.50–4.00) 0.0015
CRP (mg(l)) Initial value 21.0 (50.86) 3.3 (1.50–7.80) 7.2 (13.20) 2.6 (1.30–4.20) 0.4037
NYHA Initial value 2.8 (0.48) 3.0 (2.50–3.00) 2.5 (0.52) 2.5 (2.00–3.00) 0.0393
After 6 months 1.7 (0.58) 1.5 (1.50–2.00) 2.1 (0.67) 2.0 (2.00–2.50) 0.0060
Difference 1.06 (0.725) 1.00 (1.50–0.50) o0.001 0.33 (0.819) 0.00 (0.50–0.00) 0.0423 o0.001
EF LV (%) Initial value 25.1 (8.68) 25.0 (18.00–30.00) 23.1 (8.08) 23.0 (17.00–28.00) 0.2986
After 6 months 39.1 (10.98) 38.0 (35.00–45.00) 27.2 (9.87) 25.0 (23.00–30.00) o0.001
Difference 14.0 (13.60) 15.0 (5.00–20.00) o0.001 3.8 (12.24) 2.0 (3.00–6.00) 0.2185 0.0017
DD (mm) Initial value 64.3 (9.05) 64.0 (60.00–71.00) 68.7 (7.73) 69.0 (65.00–74.00) 0.0283
After 6 months 60.1 (9.11) 58.0 (55.00–64.00) 66.7 (8.96) 67.5 (64.00–72.00) 0.0086
Difference 4.2 (7.19) 4.0 (5.00–0.00) 0.0012 2.2 (4.56) 1.0 (5.00–1.00) 0.0156 0.3170
DS (mm) Initial value 56.3 (9.75) 56.0 (51.00–60.00) 60.7 (7.66) 62.0 (57.00–65.00) 0.0488
After 6 months 48.9 (10.39) 48.0 (44.00–53.00) 57.7 (9.38) 60.0 (56.00–63.00) 0.0008
Difference 7.3 (8.63) 6.0 (11.00–3.00) o0.001 3.1 (6.16) 2.0 (5.00–0.00) 0.0043 0.0476
EDV (ml) Initial value 216.1 (64.82) 207.0 (175.00–264.00) 249.9 (60.08) 245.0 (217.00–288.00) 0.0245
After 6 months 187.7 (64.56) 168.0 (148.00–212.00) 233.8 (69.23) 236.0 (214.00–268.00) 0.0154
Difference 28.4 (51.76) 25.0 (36.00–3.00) 0.0023 17.4 (38.36) 13.5 (36.00–1.00) 0.0197 0.5552
ESV (ml) Initial value 161.5 (59.37) 153.0 (124.00–178.00) 190.1 (53.34) 196.0 (160.00–216.00) 0.0433
After 6 months 120.4 (57.78) 109.0 (84.00–134.00) 174.1 (60.80) 181.0 (159.00–208.00) 0.0005
Difference 41.1 (52.12) 36.0 (62.00–16.00) o0.001 15.8 (40.00) 13.0 (31.00–4.00) 0.0276 0.0439
s0 (cm/s) Initial value 5.3 (2.04) 5.0 (4.50–6.00) 4.9 (1.48) 5.0 (4.00–5.50) 0.6545
After 6 months 6.7 (2.06) 6.5 (5.50–7.00) 5.5 (1.31) 5.5 (5.00–5.50) 0.0055
Difference 1.6 (2.54) 1.3 (0.50–2.50) 0.0018 0.5 (1.61) 0.0 (0.50–1.50) 0.1082 0.0820
e0 (cm/s) Initial value 6.5 (1.92) 6.5 (6.00–7.50) 5.5 (2.06) 5.5 (5.00–6.00) 0.0178
After 6 months 6.8 (2.13) 6.8 (6.00–7.50) 6.0 (1.77) 5.5 (5.00–7.00) 0.0928
Difference 0.4 (2.66) 0.3 (1.50–2.00) 0.4488 0.4 (2.29) 0.5 (0.50–1.00) 0.3404 0.8795
E/e0 Initial value 12.7 (4.50) 11.3 (10.44–13.86) 15.9 (8.93) 12.5 (11.07–17.08) 0.2234
After 6 months 10.6 (5.21) 9.5 (8.00–11.50) 10.1 (2.69) 9.7 (8.67–11.40) 0.6413
Difference 3.1 (5.43) 3.9 (5.11–0.72) 0.0035 4.9 (6.96) 3.6 (5.85–1.20) o0.001 0.8475
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 3 3 – e 3 4 0e336European Association of Echocardiography [18]. Tissue Doppler
imaging (TDI) was performedwith pulse-wave method in apical
four-chamber projection at septal and lateral edges of mitral
annulus (the average of both measurements is featured) and at
free edge of tricuspidal annulus. All findings were electronically
archived. Initial echocardiography was performed71 day from
the EMB and control echocardiography at 6 months714 days
from the initial examination by the same investigator using the
same machine. Cardiological examination and evaluation of
functional status were also assessed.
4.1. Statistics
Monitored parameters were described using descriptive ana-
lysis and initial values were compared with the values
observed after 6 months. Furthermore, a comparison was
made between both groups of patients according to the
presence or absence of inflammatory infiltration in myocar-
dium and also according to the presence or absence of
microbial (viral) genome in myocardium.
Results are presented as an average value with standard
deviation and as a median with 95% confidence interval.
Becausemost of themonitored parameters do not show normal
distribution (Shapiro–Wilk test), non-parametric tests were
performed. The change in each parameter after 6 months from
the beginning was evaluated using the paired Wilcoxon test.
Mann–Whitney test was used for comparison of parameters
between both groups according to the positive/negative finding.
All analyses were performed at the 5% significance level (i.e.
p-values o0.05 were considered statistically significant).5. Results
Seventy patients with mean age of 46712 years were enrolled.
In the whole group LVEF was 2478%, NYHA class classification
2.670.5 and duration of symptoms 3.272.8 months. When
patients were divided according to immunohistological analy-
sis (IH), 35 patients (i.e. 50%) had positive findings that means
presence of inflammatory infiltration in myocardium (IHþ)
and 35 patients (50%) had negative findings (IH). The initial
LVEF in IHþ group was 2579% and NYHA class 2.870.5; in
IH group LVEF was 2378% and NYHA class 2.570.5. The
difference in LVEF between the two groups was not statistically
significant, while the difference in NYHA class classification was
statistically significant (po0.05). In the 6-month follow-up LVEF
improved in IHþ group up to 39711% (po0.001) and NYHA class
classification to 1.770.6 (po0.001). There was no statistically
significant change in LVEF (to 27710%) in IH group, whereas
change in NYHA classification was significant (2.170.7, po0.05).
When comparing changes between the two groups, LVEF
(po0.01) as well as NYHA classification (po0.001) has signifi-
cantly more improved in the IHþ group. Other evaluated para-
meters are listed in Table 1.
When patients were divided according to PCR results, PCR
positive result (PCRþ) was found in patients where viral
genome was detected in myocardium; it was found in 43
cases (i.e. 61%). In 39 of them PVB19 was present (i.e. 91%
from all PCRþ, corresponding to 56% from all patients). (Fig. 1
shows representation of viruses.) Initial characteristics of
negative
PVB19
PVB19 + HHV6
PVB19 + HSV1 
PVB19 + EBV
PVB19 + CMV 
CMV
EBV 
HSV1
negative
CMV
PVB19 + HSV1
PVB19 + HHV6
PVB19
HSV1EBVPVB19 + CMV
PVB19 + EBV
Fig. 1 – PCR findings (representation of individual viruses).
PVB19 parvovirus B19, HHV6 human herpesvirus 6, HSV1
herpes simplex virus 1, EBV Ebstein-Barr virus, CMV
cytomegalovirus.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 3 3 – e 3 4 0 e337PCRþ and PCR groups did not differ: LVEF in the PCRþ group
was 2578%, NYHA class classification 2.670.5; in PCR LVEF
2278% and NYHA class 2.770.6. There were statistically
significant changes in LVEF in PCRþ group (EF LK 34712%;
po0.01) as well as in PCR group (LVEF 32712%; po0.001) at
6-month follow-up. There were no statistically significant
differences comparing both groups. NYHA classification had
a statistically significant decrease in both groups: in PCRþ
group to 1.970.6 (po0.001) and in PCR to 2.070.7 (po0.001);
there was also no statistically significant difference between
both groups. For other evaluated parameters see Table 2.6. Discussion
The issue of the inflammatory cardiomyopathy has become the
subject of interest again in recent years. It was caused mainly
due to new diagnostic methods that significantly improved
our ability to determine this diagnosis and the fact that on the
basis of more exact diagnosis new options of specific treatment
appeared (antiviral therapy, immunosuppressive therapy) [8,12,
13,19,16,17,19–21]. Despite significant advances in non-invasive
diagnosis based on nuclear magnetic resonance imaging (MRI)
[22–24], EMB is considered the gold standard for diagnosis of ICM
today [5,11,17,25,26]. Extensive use of biopsy diagnostics was
preceded by improved instrumentation allowing the safe EMB
execution with low risk of periprocedural complications, and in
particular the introduction of immunohistological methods forthe evaluation of biopsy samples which brought higher sensitiv-
ity of this examination preceded the boom in biopsy based
diagnostics [14,15,27]. Immunohistological evaluation comple-
mented the histological examination used before (e.g. in Myo-
carditis Treatment Trial) which itself proved to be less sensitive
[28–30]. The presence of inflammatory infiltration was in a few
trials with a long term follow-up determined as a negative
prognostic factor [9,11]. Our results, however, show that at least
in short-term follow-up the presence of myocarditis (group of
IHþ, ICM) is associated with a statistically significant improve-
ment in echocardiographic and clinical findings that were not
found in most parameters in the group of patients with no
evidence of inflammation (IH, DCM)—see Table 1. Similar
results were presented earlier by Zimmermann et al. [31] who
described improvement in echocardiographic parameters in
patients with biopsy-detected inflammation of myocardium as
well as we did. In our study, there was a significant improvement
inmany parameters (systolic diameter of LV, end-systolic volume
of LV, end-diastolic diameter of LV, end-diastolic volume of LV,
E/e0 ratio, systolic velocities of movement of mitral and tricuspid
annulus, TAPSE) in the group of patients with ICM. In the group
with non-inflammatory DCM improvement also occurred in
some parameters—in addition to NYHA classification there
was a decrease in systolic and diastolic diameters of LV, end-
systolic and end-diastolic volume of LV and E/e0 ratio. But in
most parameters the change was not as significant as in ICM
group. Duration of symptoms in IHþ group was shorter than in
IH group (2.672.9; respectively 3.872.6; po0.01), while the
value of CRP was similar in both groups (median 3.3 vs.
2.6mg/l, p¼n.s.).
As already pointed out the integral part of biopsy samples
assessment is the detection of microbial genome (mainly
viral) in myocardium (mostly by PCR method). Changes in the
incidence of different types of viruses have been described in
the last years. Originally, enteroviruses and adenoviruses
were considered the most frequent cause of viral myocarditis;
currently PVB19 and also HHV6 are mainly found to be the
cause what correlates to our findings [3,32,33]. The predomi-
nance of PVB19 in our group was very strong—this virus
isolated or in combination with another virus appeared
in 91% of all positive subjects (Fig. 1). Searching for the
meaning of the presence of PVB19 in samples from myocar-
dium is currently one of the most discussed issues. It is not
only the most frequently captured virus in myocardium of
patients with DCM, but this virus is also very often present (in
50–80%!) in myocardium of patients with normal LV function
undergoing cardiac surgery e.g. for valvular heart disease or
ischemic heart disease [32,34]. Other trials report higher
incidence of presence of PVB19 in patients with inflammatory
cardiomyopathy than in patients with non-inflammatory
cardiomyopathy [35], whereas some other ones conversely
describe PVB19 as ‘‘an innocent bystander’’ with no relation
to the current myocardium impairment [34,36,37]. Qualitative
analysis is essential and at least in case of PVB19 quantitative
analysis also seems to be necessary. Results of some trials
showed that a low viral load of PVB19 is not able to induce
myocarditis [34,38]. In this context it is important to empha-
size that in all our positive cases of PVB19 the viral load was
assessed as low and was below 500 copies/mg of nucleic acid
which is considered a boundary necessary for the induction
Table 2 – Comparison of groups of patients according to viral presence or absence in myocardium.
Parameter PCR positive (N¼43) PCR negative (N¼26)
Mean (SD) Median (95% CI) p-Value Mean (SD) Median (95% CI) p-Value p-Value
Age(years) Initial value 45.9 (13.44) 49.0 (42.00–51.00) 44.8 (9.89) 45.0 (41.00–50.00) 0.5154
Duration of symptoms (months) Initial value 3.6 (3.17) 3.0 (2.00–3.50) 2.8 (2.16) 1.5 (1.00–4.00) 0.4088
CRP (mg(l)) Initial value 11.1 (35.06) 2.7 (1.40–4.60) 18.9 (41.06) 3.3 (1.50–4.80) 0.4557
NYHA Initial value 2.6 (0.49) 2.5 (2.50–3.00) 2.7 (0.55) 3.0 (2.50–3.00) 0.2257
After 6-months 1.9 (0.63) 2.0 (1.50–2.00) 2.0 (0.71) 2.0 (1.50–2.50) 0.5238
Difference 0.68 (0.840) 0.50 (1.00–0.50) o0.001 0.72 (0.867) 0.50 (1.50–0.00) 0.0006 0.9526
LV EF (%) Initial value 25.3 (8.46) 25.0 (20.00–30.00) 22.4 (8.16) 21.0 (17.00–28.00) 0.2130
After 6-months 34.0 (12.16) 31.5 (28.00–42.00) 32.4 (11.88) 30.0 (25.00–38.00) 0.6169
Difference 8.4 (12.87) 5.0 (2.00–11.00) 0.0095 9.6 (15.56) 5.0 (1.00–20.00) o0.001 0.9122
DD (mm) Initial value 66.2 (8.37) 66.0 (64.00–69.00) 67.2 (9.36) 68.0 (62.00–74.00) 0.6376
After 6-months 63.1 (9.70) 63.5 (56.00–69.00) 63.6 (9.54) 64.0 (55.00–70.00) 0.9224
Difference 3.0 (6.34) 2.5 (4.00–0.00) 0.0041 3.6 (5.79) 3.0 (6.00–0.00) 0.0020 0.5586
DS (mm) Initial value 57.7 (8.67) 58.0 (56.00–62.00) 59.8 (9.70) 61.5 (52.00–68.00) 0.3273
After 6-months 52.9 (10.63) 52.0 (48.00–59.00) 53.6 (11.31) 56.0 (45.00–60.00) 0.8711
Difference 4.7 (7.80) 4.0 (6.00–0.00) o0.001 6.3 (7.84) 4.0 (9.00–2.00) o0.001 0.3734
EDV (ml) Initial value 229.7 (62.34) 228.0 (207.00–249.00) 239.6 (69.21) 250.5 (197.00–288.00) 0.5236
After 6-months 208.3 (71.04) 204.5 (158.00–243.00) 212.3 (70.35) 214.0 (152.00–255.00) 0.8610
Difference 21.0 (47.70) 16.0 (31.00–3.00) 0.0100 27.7 (42.68) 26.0 (46.00–5.00) 0.0020 0.4030
ESV (ml) Initial value 171.3 (54.15) 173.0 (153.00–196.00) 183.3 (64.93) 189.0 (128.00–238.00) 0.4137
After 6-months 144.0 (63.24) 130.5 (110.00–175.00) 150.1 (68.22) 159.0 (91.00–190.00) 0.7755
Difference 26.3 (46.66) 24.0 (34.00–1.00) 0.0009 33.2 (51.04) 28.0 (40.00–8.00) 0.0014 0.6085
s0 (cm/s) Initial value 5.2 (1.84) 5.0 (4.50–5.50) 5.0 (1.67) 4.5 (4.00–6.00) 0.5841
After 6-months 6.1 (1.90) 5.5 (5.50–6.50) 6.4 (1.77) 6.0 (5.50–7.00) 0.5147
Difference 0.9 (2.07) 0.5 (0.00–1.50) 0.0174 1.4 (2.43) 1.0 (0.00–2.00) 0.0848 0.4556
e0 (cm/s) Initial value 6.0 (1.95) 6.0 (5.00–6.50) 6.0 (2.23) 6.0 (4.50–7.00) 0.9685
After 6-months 6.2 (1.88) 6.0 (5.50–7.00) 6.7 (2.18) 6.3 (5.00–8.50) 0.4030
Difference 0.2 (2.18) 0.5 (0.50–1.00) 0.5823 0.5 (2.85) 0.0 (1.50–3.00) 0.2678 0.6145
E/e0 Initial value 13.9 (6.19) 12.0 (11.17–15.50) 15.3 (8.88) 12.2 (10.44–16.44) 0.8472
After 6-months 10.6 (4.67) 9.8 (8.60–11.40) 9.8 (3.05) 9.3 (8.38–10.93) 0.6984
Difference 4.0 (6.11) 3.7 (5.33–1.33) o0.001 4.2 (6.57) 3.7 (6.48–0.92) 0.0015 0.8075
RV (mm) Initial value 34.8 (5.76) 35.0 (33.00–38.00) 35.5 (5.35) 35.0 (31.00–39.00) 0.7327
After 6-months 33.2 (5.75) 34.0 (30.00–36.00) 33.3 (5.23) 31.0 (30.00–37.00) 0.8303
Difference 1.5 (6.45) 1.0 (4.00–0.00) 0.1308 2.1 (5.04) 2.0 (5.00–0.00) 0.0504 0.6077
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 3 3 – e 3 4 0 e339of inflammation [38]. But even this concept based on quanti-
tative analysis of viral load was recently challenged by the
results of German authors who assessed viral activity by
determining the viral mRNA and demonstrated that even
though the viral load of PVB19 is low, it may lead to active
viral replication what reflects the increased level of mRNA
(H.-P. Schultheiss—oral presentation at the ESC Congress,
2012).
Another reason for the indication of EMB in patients with
DCM is the possibility of specific treatment administration.
Before the immunosuppressive or antimicrobial treatment is
used it is essential to know the findings from EMB (both
immunohistochemistry and microbiology). The immunosup-
pressive treatment added to the standard therapy of heart
failure may bring benefits when inflammation is proven
and PCR is negative [16,19]. On the contrary, immunosup-
pressive therapy in patients with the presence of viruses in
myocardium led to the deterioration of status in these
individuals [39]. Immunosuppressive treatment in the
absence of inflammation is not meaningful. For the antiviral
therapy there is much less data. According to some trials
interferon treatment that leads to the eradication of adeno-
viruses and enteroviruses from myocardium brings improve-
ment in the echocardiographic parameters [8], what in turn
other authors did not confirm [40]. Examining the effect of
specific treatment, however, was not the subject of our study
and patients enrolled to the study received only the standard
therapy of heart failure. Currently, a randomized multicentric
academic study CZECH-ICIT, which was created by the
co-operation of two Czech institutions (Department of
Cardiovascular Diseases, St. Anne’s University Hospital—
International Clinical Research Center and Masaryk Univer-
sity in Brno and 2nd Internal Department—Clinical Depart-
ment of Cardiology and Angiology, 1st Medical Faculty,
Charles University of Prague), is initiated and will focus on
immunosuppressive treatment of patients with ICM.7. Conclusion
Patients with recent onset of LV dysfunction and biopsy
proved myocarditis have been found to show a more sig-
nificant improvement in LV function and functional status in
comparison to the group with no evidence of inflammatory
infiltration in 6-month follow up. Conversely, the presence or
absence of viruses in myocardium had no significant effect
on the changes in these parameters.Acknowledgments
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